company background image
AZYO

Aziyo Biologics NasdaqGM:AZYO Stock Report

Last Price

US$7.00

Market Cap

US$95.3m

7D

10.9%

1Y

-33.7%

Updated

28 Jun, 2022

Data

Company Financials +
AZYO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AZYO Stock Overview

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets.

Aziyo Biologics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aziyo Biologics
Historical stock prices
Current Share PriceUS$7.00
52 Week HighUS$11.10
52 Week LowUS$4.10
Beta0
1 Month Change11.29%
3 Month Change29.63%
1 Year Change-33.71%
3 Year Changen/a
5 Year Changen/a
Change since IPO-51.72%

Recent News & Updates

Shareholder Returns

AZYOUS BiotechsUS Market
7D10.9%10.3%6.3%
1Y-33.7%-24.5%-18.8%

Return vs Industry: AZYO underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: AZYO underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is AZYO's price volatile compared to industry and market?
AZYO volatility
AZYO Average Weekly Movement11.1%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: AZYO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: AZYO's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015157Ron Lloydhttps://www.aziyo.com

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons.

Aziyo Biologics Fundamentals Summary

How do Aziyo Biologics's earnings and revenue compare to its market cap?
AZYO fundamental statistics
Market CapUS$95.34m
Earnings (TTM)-US$27.91m
Revenue (TTM)US$46.00m

2.1x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AZYO income statement (TTM)
RevenueUS$46.00m
Cost of RevenueUS$29.03m
Gross ProfitUS$16.97m
Other ExpensesUS$44.89m
Earnings-US$27.91m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.05
Gross Margin36.90%
Net Profit Margin-60.68%
Debt/Equity Ratio350.3%

How did AZYO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AZYO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AZYO?

Other financial metrics that can be useful for relative valuation.

AZYO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.1x
Enterprise Value/EBITDA-4.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does AZYO's PS Ratio compare to its peers?

AZYO PS Ratio vs Peers
The above table shows the PS ratio for AZYO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average269x
CRDF Cardiff Oncology
266.5x93.4%US$96.1m
SQZ SQZ Biotechnologies
3.9x68.8%US$94.9m
CADL Candel Therapeutics
802.3x72.0%US$100.1m
SURF Surface Oncology
3.2x53.2%US$99.4m
AZYO Aziyo Biologics
2.1x15.6%US$95.3m

Price-To-Sales vs Peers: AZYO is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (269x).


Price to Earnings Ratio vs Industry

How does AZYO's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: AZYO is good value based on its Price-To-Sales Ratio (2.1x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is AZYO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AZYO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.1x
Fair PS Ratio3.3x

Price-To-Sales vs Fair Ratio: AZYO is good value based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).


Share Price vs Fair Value

What is the Fair Price of AZYO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AZYO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AZYO's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AZYO's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Aziyo Biologics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AZYO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AZYO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AZYO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AZYO's revenue (15.6% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: AZYO's revenue (15.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AZYO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Aziyo Biologics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-26.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AZYO is currently unprofitable.

Growing Profit Margin: AZYO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AZYO is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.

Accelerating Growth: Unable to compare AZYO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AZYO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: AZYO has a negative Return on Equity (-425.58%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Aziyo Biologics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AZYO's short term assets ($41.1M) exceed its short term liabilities ($27.3M).

Long Term Liabilities: AZYO's short term assets ($41.1M) exceed its long term liabilities ($26.0M).


Debt to Equity History and Analysis

Debt Level: AZYO's net debt to equity ratio (13.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if AZYO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AZYO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AZYO has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 29.2% each year.


Discover healthy companies

Dividend

What is Aziyo Biologics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AZYO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AZYO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AZYO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AZYO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AZYO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Ron Lloyd (60 yo)

4yrs

Tenure

US$1,609,657

Compensation

Mr. Ronald K. Lloyd, also known as Ron, has been President, Chief Executive Officer and Director of Aziyo Biologics, Inc. from June 2018. Mr. Lloyd served as Executive Vice President and President of Hospi...


CEO Compensation Analysis

Compensation vs Market: Ron's total compensation ($USD1.61M) is above average for companies of similar size in the US market ($USD748.70K).

Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AZYO's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: AZYO's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.2%.


Top Shareholders

Company Information

Aziyo Biologics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Aziyo Biologics, Inc.
  • Ticker: AZYO
  • Exchange: NasdaqGM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$95.341m
  • Shares outstanding: 13.62m
  • Website: https://www.aziyo.com

Number of Employees


Location

  • Aziyo Biologics, Inc.
  • 12510 Prosperity Drive
  • Suite 370
  • Silver Spring
  • Maryland
  • 20904
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.